Advertisement





Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2006; 47:1143-1149, doi:10.1016/j.jacc.2005.12.022 (Published online 21 February 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2005.12.022v1
47/6/1143    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ribichini, F.
Right arrow Articles by Vassanelli, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ribichini, F.
Right arrow Articles by Vassanelli, C.

CLINICAL RESEARCH: ATHEROSCLEROSIS

Cellular Immunostaining of Angiotensin-Converting Enzyme in Human Coronary Atherosclerotic Plaques

Flavio Ribichini, MD*,*, Francesco Pugno, MD{dagger}, Valeria Ferrero, MD*, Gianni Bussolati, MD, FRCPath{ddagger}, Mauro Feola, MD{dagger}, Paolo Russo, MD§, Carlo Di Mario, MD||, Antonio Colombo, MD|| and Corrado Vassanelli, MD*

* Catheterization Laboratory, Ospedale Maggiore della Carità, Universita’ del Piemonte Orientale, Novara, Italy
{dagger} Ospedale Santa Croce e Carle, Cuneo, Italy
{ddagger} Dipartimento di Scienze Biomediche dell’Universita’ di Torino, Torino, Italy
§ Clinica Villa Maria Pia, Torino, Italy
|| Centro Cuore Columbus, Ospedale San Raffaele, Milano, Italy

Manuscript received May 31, 2005; revised manuscript received August 30, 2005, accepted September 8, 2005.

* Reprint requests and correspondence: Dr. Flavio Ribichini, Director Catheterization Laboratory, Università del Piemonte Orientale, Ospedale Maggiore della Carità, Corso Mazzini 18, 28100 Novara, Italy. (Email: flavio.ribichini{at}med.unipmn.it).

OBJECTIVES: The aim of this study was to determine the cellular localization of angiotensin I-converting enzyme (ACE) in the atherosclerotic plaque and its correlation with inflammation and cellular proliferation.

BACKGROUND: Angiotensin I-converting enzyme inhibitors reduce the incidence of vascular events; therefore, tissue ACE may play a determinant role in the pathophysiology of the atherosclerotic plaque.

METHODS: Histology and immunocytochemistry of de novo coronary plaques retrieved with directional coronary atherectomy from 141 patients were analyzed: 87 with stable angina, 39 with subacute unstable angina, and 15 with acute unstable angina.

RESULTS: Compared with stable patients, unstable patients showed more thrombotic lesions (72% vs. 27%, p < 0.0001), smaller areas of fibrous plaque (2.3 ± 1.2 mm2 vs. 2.8 ± 1.1 mm2, p = 0.02), higher cellular proliferative score (0.78 ± 0.9 vs. 0.27 ± 0.6, p = 0.003), larger content of ACE-stained cells (26.3 ± 23% vs. 12.6 ± 15%, p = 0.005) and larger areas of inflammation as identified by CD68 immunostaining (29.5 ± 22% vs. 20.2 ± 19%, p = 0.02). A significant linear correlation was found between CD68- and ACE-stained areas (mm2) among unstable patients (r = 0.6, p = 0.0001), but it was absent among stable patients (r = 0.006, p = 0.9). Co-localization of ACE, CD68, and alpha-actin was confirmed by double immunostaining. Patients with Ki-67–positive staining as an index of cell proliferation showed also significantly larger areas of ACE immunoactivity (p = 0.004).

CONCLUSIONS: Our data demonstrate ACE immunoactivity in inflammatory and proliferative cells of coronary atherosclerotic plaques. In particular, patients with unstable angina showed larger areas of ACE immunoactive tissue and proliferating cells compared with stable patients. These observations support a role of the enzyme in the pathophysiology of coronary unstable plaques and suggest potentially different effects of ACE inhibitors according to clinical presentation.

Abbreviations and Acronyms
  ACE = angiotensin I-converting enzyme
  ACS = acute coronary syndromes
  DCA = directional coronary atherectomy
  HPF = high-power fields
  ID = insertion/deletion
  MI = myocardial infarction
  SMC = smooth muscle cells




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Takata, J. Liu, F. Yin, A. R. Collins, C. J. Lyon, C.-H. Lee, A. R. Atkins, M. Downes, G. D. Barish, R. M. Evans, et al.
PPAR{delta}-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis
PNAS, March 18, 2008; 105(11): 4277 - 4282.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen
Angiotensin-Converting Enzyme and Vascular Remodeling
Circ. Res., August 31, 2007; 101(5): 441 - 454.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement